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ABSTRACT
Objectives: To estimate models, via ordinary least squares regression, for
predicting Euro Qol 5D (EQ-5D), Short Form 6D (SF-6D), and 15D
utilities from scale scores of the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).
Methods: Forty-eight gastric cancer patients, split up into equal sub-
groups by age, sex, and chemotherapy scheme, were interviewed, and the
survey included the QLQ-C30, SF-36, EQ-5D, and 15D instruments,
along with sociodemographic and clinical data. Model predictive ability
and explanatory power were assessed by root mean square error (RMSE)
and adjusted R2 values, respectively. Pearson’s r between predicted and
reported utility indices was compared. Three random subsamples, half in
size the initial sample, were created and used for “external” validation of
the modeling equations.
Results: Explanatory power was high, with adjusted R2 reaching 0.909,
0.833, and 0.611 for 15D, SF-6D, and EQ-5D, respectively. After
normalization of RMSE to the range of possible values, the prediction
errors were 12.0, 5.4, and 5.6% for EQ-5D, SF-6D, and 15D, respectively.
The estimation equations produced a range of utility scores similar to
those achievable by the standard scoring algorithms. Predicted and
reported indices from the validation samples were comparable thus con-
ﬁrming the previous results.
Conclusions: Evidence on the ability of QLQ-C30 scale scores to validly
predict 15D and SF-6D utilities, and to a lesser extent, EQ-5D, has been
provided. The modeling equations must be tried in future studies with
larger and more diverse samples to conﬁrm their appropriateness for
estimating quality-adjusted life-year in cancer-patient trials including only
the QLQ-C30.
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Introduction
Cost-utility analyses (CUA) require the calculation of quality-
adjusted life-years (QALYs), which account for quality (morbid-
ity) and duration (mortality) of life in a single outcome measure.
The quality adjustment is based on a set of weights (utilities),
which reﬂect the preferences of the community for a certain health
state relative to others. These weights are assumed to provide
interval scaled information, where 1 and 0 refer to full health and
death, respectively. Negative utilities may also occur if very severe
health states are evaluated as being worse (i.e., less preferable)
than death. Utilities are preference based and derived by the
individual either via direct valuation techniques, such as standard
gamble (SG), time trade-off (TTO), and rating scale, or indirectly
via generic health-related quality of life (HRQoL) measures, such
as the 15D [1], the Health Utility Index (HUI) [2,3], the Euro Qol
5D (EQ-5D) [4] or the Short Form 6D (SF-6D) [5], for which
scoring algorithms have been developed to yield community-
based health utility estimates. According to recent review study,
HRQoL instruments were used in 76% of the studies in which
QALYs were calculated from patient measurements, with
approximately 60% of them involving the EQ-5D [6].
When the interest is in measuring the HRQoL of patients,
disease-speciﬁc instruments are often preferred to generic ones
because they focus on particular health problems and tend to be
more sensitive to clinically important differences [7]. Neverthe-
less, disease-speciﬁc measures do not have utility scoring systems,
and CUA requires a single, preference-based score so that QALYs
can be calculated. On the other hand, using both types of instru-
ments adds to the burden imposed on patients for completing
questionnaires. A solution to this problem is to attempt to predict
utilities by “mapping,” i.e., regressing preference-based indices
against dimension or item scores of disease-speciﬁc measures and
thus obtain estimation models that can be used to subsequently
calculate QALYs [8].
Mapping between measures is a fairly new research area, and,
according to a recent review of studies mapping nonpreference to
preference-based measures, the majority of such studies have
been published or produced after 2000 [9]. The most popular
target measure has been by far the EQ-5D, followed by the
HUI2/HUI3 and the SF-6D. Interestingly, the 15D has been
involved in only one mapping effort, in which the starting
measure was a self-assessed health question (and not a condition-
speciﬁc instrument) [10]. Disease-speciﬁc measures having been
used in mapping studies covering asthma [8], inﬂammatory
bowel disease [11], obesity [12], angina [13], dental conditions
[14], intermittent claudication [15], and other diseases. As for
cancer, the European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) has
been used to predict EQ-5D indices and dimensions with ordi-
nary least squares (OLS) and probit regression, respectively. The
model explaining EQ-5D values predicted well, whereas predic-
tion of EQ-5D values based on predicted levels for each dimen-
sion was less successful [16]. The QLQ-C30 has also been used,
along with the Functional Assessment of Cancer Therapy—
Prostate Questionnaire, to construct and validate an EQ-5D
prediction model for metastatic hormone-refractory prostate
cancer patients, and showed good predictive validity [17].
The purpose of this study was to establish, using a com-
mon data set and OLS regression, empirical mapping relation-
ships between the cancer-speciﬁc QLQ-C30 and three
Address correspondence to: Nick Kontodimopoulos, Faculty of Social
Sciences, Hellenic Open University, Bouboulinas 57, 26222, Patras,
Greece. E-mail: nkontodi@otenet.gr
10.1111/j.1524-4733.2009.00569.x
Volume 12 • Number 8 • 2009
V A L U E I N H E A LT H
© 2009, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/09/1151 1151–1157 1151
preference-based generic instruments, the EQ-5D, SF-6D, and
15D, and to compare performance of the resulting models in
terms of predictive ability and goodness of ﬁt. The sample com-
prised of gastric cancer patients currently on chemotherapy.
Although the QLQ-C30 has been designed to measure different
HRQoL concepts than the preference-based instruments, demon-
stration of robust relationships and testing of the models with
external “validation” samples can increase the conﬁdence
placed on utilities obtained in trials not including any generic
instruments.
Methods
Instruments
The EuroQol EQ-5D consists of a descriptive health state clas-
siﬁcation system with ﬁve domains (mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression) and three
severity levels in each (no problems, some problems, and extreme
problems) [4]. Combining one level from each domain deﬁnes
243 different health states ranging from full to worst health.
Direct valuations for 42 health states were elicited from 3395
persons of the UK general public using the TTO method. Regres-
sion techniques were applied to interpolate values for the other
health states, and the utilities range from -0.59 to 1.00 [18]. The
EQ-5D was found to be applicable and adaptable to the Greek
environment [19], and its construct validity was demonstrated
using a large sample of the Greek general population [20].
The SF-6D consists of a health status classiﬁcation system
with six domains (physical functioning, role limitations, social
functioning, pain, mental health and vitality) and four to six
severity levels in each, giving 18,000 unique health states. The
scoring model is based on the SG utilities of 836 members of the
UK general population, and, like the EQ-5D, regression models
predicted utility scores ranging from 0.30 (worst health) to 1.00
(full health) for each of the possible health states [5]. The SF-6D
is derived from the SF-36 (used in this study), which has been
translated into Greek, and its reliability and validity were estab-
lished in a sample of 1007 adults living in the greater Athens area
[21,22]. The only Greek study having used the SF-6D in a cost-
utility analysis demonstrated it to be satisfactorily valid [23].
The 15D is a generic HRQoL instrument with 15 dimensions:
mobility, vision, hearing, breathing, sleeping, eating, speech,
elimination, usual activities, mental function, discomfort and
symptoms, depression, distress, vitality, and sexual activity, with
each divided into ﬁve possible response levels, structured from
the best to the worst possible health condition [1]. The valuation
system of the 15D is based on an application of the multiattribute
utility theory. The single index (15D score) on a 0 to 1 scale
(death and full health, respectively) is calculated from the health
state descriptive system by using a set of population-based pref-
erence or utility weights. A weight for each level of each dimen-
sion is obtained by multiplying the level value by the importance
weight of the dimension at that level. The level values on the 0 to
1 scale, reﬂecting the goodness of the levels relative to no prob-
lems on the dimension and to being dead, and the importance
weights summing up to unity, have been elicited from represen-
tative population samples by using a combination of rating scale
and magnitude estimation methods (ratio scale with quantiﬁers)
[1]. The 15D Questionnaire is relatively brief, easy to use, and
has been shown to be reliable, valid, acceptable, and responsive.
It is the only utility instrument with a Greek scoring algorithm
[24]. Nevertheless, because of the absence of national scoring
weights for the other two instruments, the original Finnish
scoring was used in this study.
The EORTC QLQ-C30 is a popular instrument for measur-
ing general cancer quality of life [25]. Most of the 30 questions
have four response levels (not at all, a little, quite a bit, and very
much), with two questions relying on a 7-point scale. Raw ques-
tionnaire responses are transformed to produce scores on ﬁve
function scales (physical, role, emotional, cognitive, and social
functioning) and nine symptom scales along with a scale repre-
senting global quality of life. Higher functional scale scores
(range: 0–100) indicate better HRQoL, but higher symptom
scale/item scores indicate higher level of symptoms. The scales
have undergone psychometric testing, based on classical test
theory, which has yielded favorable results [26]. The Greek
version has also been shown to be reliable in a sample of cancer
patients under palliative care [27].
Sample and Data Collection
To ensure that major patient characteristics were represented in
the sample, a nonprobability quota-based sampling procedure
was employed. Equiproportional groups were formed according
to sex, age (<60 and60 years old) and treatment scheme (potent
vs. mild which may result in more or less undesired side effects,
respectively). All the information was collected between Novem-
ber 2007 and March 2008. Patients were approached for partici-
pation during their visit to the “Theagenio” Cancer Hospital in
Thessaloniki for chemotherapy (before treatment). Selected
patients had previously attended two to four chemotherapy ses-
Table 1 Descriptive statistics for EQ-5D, SF-6D, and 15D utilities and QLQ-C30 scales
Statistics
Utility scores
EORTC QLQ-C30 scales
Functional scales*
EQ-5D SF-6D 15D QL PF RF EF CF SF
Mean (SD) 0.550 (0.307) 0.606 (0.094) 0.685 (0.166) 46.35 (17.10) 57.92 (26.10) 31.60 (27.77) 59.03 (24.90) 85.42 (21.09) 42.71 (25.94)
95% CI 0.461–0.639 0.579–0.633 0.636–0.733 41.39–51.32 50.34–65.50 23.53–39.66 51.80–66.26 79.29–91.54 35.18–50.24
Median 0.620 0.603 0.696 50.00 60.00 33.33 62.50 100.00 41.67
25–75 percentiles 0.290–0.774 0.556–0.674 0.574–0.819 33.33–56.25 35.00–80.00 0.00–50.00 41.67–83.33 66.67–100.00 33.33–66.67
Min.–max. -0.349–1.000 0.362–0.852 0.235–0.981 0.00–83.33 0.00–100.00 0.00–100.00 0.00–91.67 16.67–100.00 0.00–100.00
% Floor–% ceiling 2.1–2.1 2.1–2.1 2.1–2.1 2.1–0.0 2.1–6.3 31.3–2.1 4.2–14.6 2.1–58.3 12.5–2.1
Z‡ value (P–sig.) 1.283 (0.074) 0.716 (0.684) 0.586 (0.883) 1.147 (0.144) 0.960 (0.315) 1.281 (0.075) 0.835 (0.489) 2.347 (<0.001) 0.978 (0.295)
Skewness -1.120 0.034 -0.573 -0.024 -0.435 0.460 -0.583 -1.494 0.073
*Higher functional scale scores indicate better health-related quality of life.
†Higher symptom scale/item scores indicate higher level of symptoms.
‡Kolmogorov–Smirnov test.
AP, appetite loss; CF, cognitive functioning; CI, conﬁdence interval; CO, constipation; DI, diarrhea; DY, dyspnea; EF, emotional functioning; EQ-5D, Euro Qol 5D; EORTC QLQ-C30, European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire; FA, fatigue; FI, ﬁnancial difﬁculties; NV, nausea/vomiting; PA, pain; PF, physical functioning; QL, global health
status/QoL; RF, role functioning; SF, social functioning; SF-6D, Short Form 6D; SL, insomnia.
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sions, and at least 20 days had passed since the last one. The ﬁnal
sample consisted of 48 (N = 48) gastric cancer patients, all of
which had undergone surgery. No patients were suffering from
metastases of the cancer to other organs, which could further
affect their HRQoL negatively. Tominimize missing data, patients
were interviewed by the same interviewer, and the survey included
the EQ-5D, SF-36, and 15D instruments, the cancer-speciﬁcQLQ-
C30, and common demographic questions. Disease-related data
were taken from the patients’ history. The interview lasted
approximately 30 to 40minutes, and none of the patients declined
participation. The hospital’s Review Board ethically approved the
study and all participants provided informed consent.
Analysis
The Kolmogorov-Smirnov test was used to demonstrate distri-
bution normality of EQ-5D, SF-6D, 15D, and QLQ-C30 scale
scores. Although this was clearly not a QLQ-C30 validation
study, some validity evidence was required before actually
testing the predictive ability of the instrument. Pearson’s corre-
lations between QLQ-C30 and SF-36 scales were used to assess
convergent construct validity. Based on the literature [28,29], it
was hypothesized that scales measuring similar dimensions of
HRQoL should be strongly correlated (at least >0.50). QLQ-
C30 scale scores were also compared between subjects to
assess known-groups construct validity. It was hypothesized
that younger subjects and those not reporting coronary disease
would have better HRQoL, as would those undergoing less
potent chemotherapy. Internal consistency reliability of each
QLQ-C30 scale was assessed using Cronbach’s alpha, and the
0.70 standard for group-level comparisons was adopted [30].
Ordinary least squares (OLS) regression was used to model
the EQ-5D, SF-6D, and 15D using QLQ-C30 scale scores as
predicting variables. The models deﬁned in this study are addi-
tive, implying linear independence between predictor variables.
Reported utility indices were modeled via a stepwise inclusion
procedure, which identiﬁed signiﬁcant QLQ-C30 predictors. Full
OLS models (all QLQ-C30 scales entered as predictors) were
run, and their performance was similar to the stepwise models,
which were chosen for parsimony. The full model results are
available from the authors. Furthermore, forward and backward
variable selection procedures were tried as well, and converged to
equivalent solutions.
Because the objective of this study was to predict EQ-5D,
SF-6D, and 15D indices of patients with a given QLQ-C30
proﬁle, and not to explain the relationship between the instru-
ments, explanatory power (adjusted R2) was not the most impor-
tant indicator (although reported). A better method used in many
studies has been to examine the difference between predicted and
reported utility indices at the individual level by calculating the
root mean square error (RMSE). This was taken as the perfor-
mance criterion of the models, and the smaller this value, the
better the performance. RMSE was normalized to the range of
possible scores of each instrument (1.59 for EQ-5D, 0.699 for
SF-6D, and 0.894 for 15D) and expressed as %RMSE. Pearson’s
correlation coefﬁcients between reported and predicted indices
were examined. The range of achievable utilities from the
mapping equations was compared with the respective range of
the standard scoring algorithms.
The robustness of prediction models is not sufﬁciently estab-
lished with “within-sample” testing, i.e., when the data set on
which the models were estimated and the data set on which the
predictions were ﬁtted are one and the same. In light of the
unavailability of external data sets, three “validation” samples
were created and used to test the modeling equations generated
by the full sample. These samples were created by randomly
selecting half the sample, and thus were at least partly different
from the estimation sample. The procedure was repeated three
times to enhance conﬁdence in the validation exercise. All regres-
sions were run using STATA version 8.0 (StataCorp LP, College
Station, TX), and data were analyzed using SPSS version 13.0
(SPSS Inc, Chicago, IL).
Results
Sex and age group as important demographic characteristics and
treatment scheme as a clinical factor were taken as the HRQoL-
inﬂuencing variables that should be represented in the study
sample, which was comprised of 48 patients. Based on equipro-
portional sampling, each sex group contained an equal number
of participants from four age groups: 40 to 49, 50 to 59, 60 to
69, and +70, and each was equally divided into patients on
milder chemotherapy and on a more potent scheme. From the
overall sample, 25 patients (52.1%) had 9 years (or less) of
schooling, and 30 (62.5%) were in the workforce. As for comor-
bid conditions, 14 patients (29.2%) reported diabetes, and the
same percentage suffered from coronary disease. Finally, 12
patients (25.0%) were taking tranquillizers to help them deal
with their condition.
EQ-5D, SF-6D, 15D, and QLQ-C30 descriptive statistics are
presented in Table 1. Regarding the three utilities, the 15D gave
the highest reported index (0.685), a ﬁnding that agrees with
Symptom scales/items†
FA NV PA DY SL AP CO DI FI
74.07 (25.25) 73.61 (28.11) 26.39 (20.58) 52.78 (24.63) 41.67 (34.04) 58.33 (31.13) 8.33 (20.05) 56.25 (40.19) 39.58 (26.32)
66.74 (81.41) 65.45–81.77 20.41–32.36 45.63–59.93 31.78–51–55 49.29–67.37 2.51–14.15 44.58–67.92 31.94–47.23
77.78 83.33 33.33 66.67 33.33 66.67 0.00 66.67 33.33
58.33–100.00 50.00–100.00 0.00–33.33 33.33–66.67 0.00–66.67 33.33–91.67 0.00–0.00 8.33–100.00 33.33–66.67
0.00–100.00 0.00–100.00 0.00–66.67 0.00–100.00 0.00–100.00 0.00–100.00 0.00–100.00 0.00–100.00 0.00–100.00
2.1–29.2 2.1–41.7 31.3–8.3 4.2–10.4 29.2–12.5 8.3–25.0 81.3–2.1 25.0–35.4 16.7–6.3
1.126 (0.159) 1.682 (0.007) 2.070 (<0.001) 1.831 (0.002) 1.284 (0.074) 1.425 (0.34) 3.282 (<0.001) 1.497 (0.023) 2.093 (<0.001)
-0.930 -0.725 0.083 0.196 0.219 -0.123 2.909 -0.272 0.460
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results from another study in which the same three instruments
were administered [31]. The SF-6D expectedly outscored the
EQ-5D because it has been shown to give higher scores in
samples with impaired health, in contrary to the EQ-5D, which
usually gives higher scores in healthier populations [32,33]. The
EQ-5D scores were the most negatively skewed (i.e., they clus-
tered at the upper extreme); however, being a highly morbid
sample, only one respondent was at the EQ-5D ceiling. Floor and
ceiling effects were minimal for the other two measures as well.
None of the instruments reached their theoretically achievable
range. Kolmogorov–Smirnov Z-tests showed a normal data dis-
tribution for all three measures. As for the QLQ-C30 scales,
cognitive functioning was the highest scoring functional scale
(85.42), and role functioning the lowest (31.60), indicating best
and worst HRQoL, respectively, in these two domains. The best
symptom scale (i.e., lowest level of symptoms) was constipation
(8.33), and the worst (i.e., the most symptoms) was fatigue
(74.07).
Evidence of QLQ-C30 construct validity was provided in that
correlations for eight pairs of QLQ-C30 and SF-36 scales
hypothesized to be measuring similar dimensions of HRQoL
were strong and statistically signiﬁcant (P < 0.01) (Table 2). Pear-
son’s r ranged from 0.69 between QLQ-C30 role functioning,
and SF-36 role–physical scales to 0.89 between QLQ-C30 fatigue
and SF-36 vitality scales, supporting convergent validity. High
internal consistency was demonstrated by Cronbach’s alpha
exceeding the >0.7 criterion (0.86–0.94) in all QLQ-C30 scales
with two or more items. Construct validity was further sup-
ported by conﬁrmation of all expected score differences between
subgroups previously hypothesized to differ in HRQoL. Speciﬁ-
cally, patients <60 years reported better HRQoL scores than
those 60 years, as did patients without heart disease and
patients undergoing milder chemotherapy compared with those
on potent schemes (results not shown). All observed differences
were statistically signiﬁcant for the physical, role and cognitive
functioning QLQ-C30 domains, as well as for the fatigue,
nausea/vomiting, dyspnea, appetite loss, and diarrhea symptoms
scales.
Three scales were signiﬁcant predictors (P < 0.05 or better) of
EQ-5D indices, six scales (P < 0.05 or better) of SF-6D indices,
and four scales (P < 0.001) of 15D indices (Table 3). Global
health status was signiﬁcant in all three models, whereas role
function was the only functional scale not appearing in any
model. For all utility indices, at least two functional scales were
signiﬁcant predictors, with the physical functioning and emo-
tional functioning scales appearing in two of the models. Four
symptoms scales (pain, constipation, dyspnea, and insomnia)
also appeared in at least one of the models as signiﬁcant predict-
ing variables. These stepwise regression models can be used to
predict EQ-5D, SF-6D, and 15D utility scores, according to
equations that are created from the information in Table 3.
The explanatory power of the regression models—
represented by adjusted R2—was relatively high, indicating that
they explain large parts of the variation, especially in the case of
Table 2 Pearson’s correlation coefﬁcients between QLQ-C30 and SF-36 scales
QLQ-C30 scale
SF-36 Scale
PF RP BP GH VT SF RE MH
Global health status 0.62* 0.67* 0.53* 0.76* 0.77* 0.77* 0.28 0.51*
Physical functioning 0.87* 0.57* 0.59* 0.66* 0.70* 0.76* 0.20 0.34†
Role functioning 0.71* 0.69* 0.42* 0.82* 0.77* 0.74* 0.39* 0.56*
Emotional functioning 0.24 0.39* 0.26 0.55* 0.41* 0.54* 0.71* 0.88*
Social functioning 0.61* 0.55* 0.40* 0.68* 0.61* 0.73* 0.39* 0.61*
Fatigue 0.58* 0.69* 0.34* 0.87* 0.89* 0.71* 0.36** 0.50*
Pain 0.56* 0.53* 0.81* 0.35** 0.34** 0.45* -0.07 0.12
*P < 0.01, **P < 0.05.
Hypothesized strong correlations are indicated in italics.
BP, bodily pain; GH, general health; MH, mental health; PF, physical functioning; QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; RE, role
emotional; RP, role physical; SF, social functioning; SF-36, Short Form 36;VT, vitality.
Table 3 Multiple stepwise linear regression models
Utility QLQ-C30 predictors B SE t Signiﬁcance Adjusted R2 RMSE % RMSE*
Measuring range†
(standard algorithm)
EQ-5D Physical functioning 0.00508 0.0015 3.47 0.001 0.611 0.192 12.0% -0.184–1.186 (-0.594–1.000)
Emotional functioning 0.00313 0.0012 2.60 0.013
Global health status 0.00546 0.0023 2.35 0.023
(Constant) -0.18143 0.0916 -1.98 0.054
SF-6D Social functioning 0.00082 0.0003 2.57 0.014 0.833 0.038 5.4% 0.212–0.843 (0.301–1.000)
Global health status 0.00085 0.0005 1.74 0.090
Emotional functioning 0.00167 0.0003 5.74 <0.001
Pain -0.00122 0.0003 -3.71 0.001
Constipation -0.00110 0.0003 -3.78 <0.001
Dyspnea -0.00064 0.0003 -2.16 0.037
(Constant) 0.50842 0.0330 15.42 0.000
15D Physical functioning 0.00299 0.0005 6.02 <0.001 0.909 0.050 5.6% 0.161–1.019 (0.106–1.000)
Global health status 0.00262 0.0006 4.38 <0.001
Insomnia -0.00096 0.0002 -4.24 <0.001
Cognitive functioning 0.00198 0.0005 3.64 0.001
(Constant) 0.26114 0.0357 7.31 <0.001
*Corresponds to the normalized RMSE.
†Corresponds to the range of achievable utility values from the mapping equations compared to the standard scoring algorithms.
EQ-5D, Euro Qol 5D; QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; RMSE, root mean square error; SE, standard error of the mean;
SF-6D, Short Form 6D.
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15D and SF-6D (90.9% and 83.3%, respectively), and lower in
EQ-5D (61.1%). High explanatory power does not necessarily
imply good predictive ability as well; therefore, RMSE was the
important indicator to be examined. In terms of predictive
ability, the SF-6D model outperformed the others, with a RMSE
of 0.038. The 15D model followed, showing slightly poorer
predictive ability, i.e., RMSE = 0.050, and by far, the highest
prediction errors corresponded to the EQ-5D model, with a
RMSE of 0.192. To compare across instruments, normalized
values (i.e., % RMSE) were calculated. The results for EQ-5D,
SF-6D, and 15D prediction models were 12.0, 5.4, and 5.6%
respectively, conﬁrming that the EQ-5D model generates the
weakest predictions.
For each instrument, the measuring range of the prediction
equations was examined and compared with the range of utilities
achievable by the standard scoring algorithms. At the lower end,
the estimated SF-6D equation can generate lower values than the
standard algorithm (0.212 vs. 0.301), whereas at the upper end
the estimated EQ-5D slightly exceeded unity (1.186), as did 15D,
but just marginally (1.019). Overall, the estimated 15D measur-
ing limits were the ones closest to the standard range (i.e., 0.161–
1.019 vs. 0.106–1.000). Estimated EQ-5D, SF-6D, and 15D
utilities were compared with mean reported utilities, i.e., those
derived directly from the instruments, and the correlation was
high in all models, with Pearson’s r reaching 0.797, 0.924, and
0.959 (P < 0.01, throughout) for EQ-5D, SF-6D, and 15D,
respectively.
Correlation between reported and predicted indices, from the
three “external” data sets, was strong and statistically signiﬁcant
(P < 0.01) for all utility instruments (Table 4). It is also worth
mentioning that reported utilities were well within the 95%
conﬁdence intervals of the predicted ones. A minimally impor-
tant difference (MID)—deﬁned as the smallest score difference
which the patients perceive as beneﬁcial [34]—was reached in the
case of EQ-5D in the third validation sample because the esti-
mated difference between reported and predicted utility indices
was 0.03, which constitutes an EQ-5D MID typically reported in
the literature [35]. The same MID (0.03) has been reported for
the SF-6D [36] and the 15D [37], but was not exceeded here, and
this increases conﬁdence in the predicted utilities for these two
instruments. In the case of EQ-5D, MID estimation efforts have
resulted in higher values. In a review of eight longitudinal studies
involving 11 patient groups, MIDs ranged from -0.011 to 0.140,
and in nine of these groups exceeded 0.03 [38]. In any case,
deﬁning a valid MID for the EQ-5D calculated by the British
tariff may be futile because of the large range of utility values
generated.
Discussion
Mapping can be valuable for analyzing data from older studies in
which no preference-based instruments were used. When pos-
sible, however, it should be chosen as the alternative strategy
because generic and disease-speciﬁc instruments serve different
purposes, and one cannot substitute completely for the other.
This study attempted to predict utility indices for three widely
used instruments in economic evaluations, the EQ-5D, SF-6D,
and 15D, using patient data from an also widely used disease-
speciﬁc questionnaire. The obvious beneﬁts would be the po-
tential to perform cost-utility analyses with disease-speciﬁc
questionnaires—something not usually possible—while exploit-
ing the increased sensitivity of condition-speciﬁc instruments to
aspects of a disease usually overseen by generic ones. The disease
in question was gastric cancer, and the chosen questionnaire was
the EORTC’s QLQ-C30, which is an integrated system for
assessing the HRQoL of cancer patients.
The present study is the ﬁrst, to our knowledge, to predict
and compare utility indices for three preference-based instru-
ments using the same data set. It is also the ﬁrst to map any
disease-speciﬁc questionnaire on to the 15D. OLS regression was
used, and the models were compared mainly in terms of predic-
tive ability, and, to a lesser extent, explanatory power. Equipro-
portional groups according to age, sex, and treatment scheme
were formed, and the ﬁnal sample comprised of 48 gastric cancer
patients. Although the common source of data in similar studies
are clinical trials or large survey panel data, there have been
mapping attempts with small (<100) data sets [9].
Validation of the EORTC QLQ-C30 itself was not among the
explicit objectives of this study; however, evidence was accumu-
lated to support convergent and “known-groups” construct
validity and internal consistency reliability. The SF-36, which has
been shown to be valid and reliable in the Greek population
[21,22], was used as the “standard,” and the hypothesized strong
correlations between similar SF-36 and QLQ-C30 scales were
conﬁrmed. In light of the limited—until now—use of this instru-
ment in Greek settings, such information is important in terms of
the conﬁdence to be placed on utility indices predicted from this
cancer-speciﬁc instrument, but also adds to the existing knowl-
edge from the only previous Greek study having tested and
conﬁrmed the psychometric properties of the QLQ-C30 [27].
The purpose of this study was to derive mapping algorithms
to be applied to trial data to calculate utilities at various time
points during the course of a treatment, and thus be used to
derive QALYs. Although the prediction models were estimated in
a speciﬁc context, i.e., in gastric cancer patients under chemo-
therapy, the equations can be applied to other cancer patients
with similar QLQ-30 scores, or to cancer patients with similar
scores who are receiving chemotherapy. Based on QLQ-C30
scale scores, EQ-5D, SF-6D, and 15D utility indices were pre-
dicted via OLS regression. The models excluded patient back-
ground characteristics such as age, sex, income, and others
because this would increase model complexity, and as it has been
shown in a recent review of mapping studies “Quite modest or
negligible improvements were achieved from increasing model
complexity” [9].
Explanatory power, particularly for the 15D and SF-6D
models, was high (adjusted R2 > 0.80), implying that QLQ-C30
scales explained large parts of the variation in these two utility
indices. Because no 15D mapping attempts have been recorded in
the literature, there were obviously no results with which to
Table 4 Reported versus predicted utilities for three random validation
samples
Validation samples
Reported
utilities
Mean (95% CI)
predicted utilities Pearson’s r
Sample no. 1
EQ-5D 0.498 0.504 (0.412–0.596) 0.756*
SF–6D 0.582 0.586 (0.553–0.620) 0.908*
15D 0.653 0.652 (0.589–0.716) 0.951*
Sample no. 2
EQ-5D 0.505 0.513 (0.408–0.619) 0.842*
SF-6D 0.587 0.589 (0.555–0.623) 0.878*
15D 0.664 0.662 (0.594–0.731) 0.963*
Sample no. 3
EQ-5D 0.521 0.551 (0.435–0.668) 0.881*
SF-6D 0.605 0.612 (0.569–0.654) 0.934*
15D 0.680 0.685 (0.610–0.761) 0.971*
*P < 0.01.
CI, conﬁdence interval; EQ-5D, Euro Qol 5D; SF-6D, Short Form 6D.
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compare R2 or any other model parameters, for that matter. On
the other hand, explanatory power for the SF-6D model was
higher than relative values reported in mapping studies involving
the SF-6D and disease-speciﬁc instruments (but not the QLQ-
C30) [9,12]. As for the EQ-5D, the regression model explained
61% of its variation. This ﬁgure is in agreement with results from
a study involving the QLQ-C30 and the EQ-5D, in which two
QLQ-C30 scales, global health status, and emotional function-
ing, were signiﬁcant predictors, as in the present study [16]. In an
attempt to improve explanatory power, we incorporated squared
QLQ-C30 dimension scores into the EQ-5D estimation model;
however, the improvement was modest (R2 = 0.687). Inclusion of
interaction or power terms in estimation models is common, but
only rarely is there a noteworthy improvement. One exception is
a mapping between IBDQ to EQ-5D, where R2 increased from
0.45 to 0.69 after incorporating squared terms of dimension
scores [11].
Predictive ability of the models was highest for SF-6D
(RMSE = 0.038), followed by 15D (RMSE = 0.050), and lower
for EQ-5D (RMSE = 0.192), or in terms of normalized %RMSE
values, 5.4, 5.6, and 12.0%, respectively. The strength of
mapping usually depends on the overlap between two instru-
ments in terms of their descriptive systems. By comparing the
names of the domains, it appears that the EQ-5D is just as much
covered by the QLQ-C30 as are the SF-6D and 15D instruments.
On the other hand, the EQ-5D, because of its relative simplicity,
does not address as many of the QLQ-C30 domains as the other
two instruments, and this may explain in part the observed lower
predictive ability of the EQ-5D model. Nevertheless, some
dimensions (e.g., pain) are heavily weighted in the original
scoring algorithms (e.g., SF-6D and EQ-5D), but are not neces-
sarily predictive of the respective utility. For example, in this
study, the QLQ-C30 pain dimension is predictive of only SF-6D
(and not EQ-5D) utilities, implying that overlap alone cannot
explain the reduced predictive ability of the EQ-5D model.
The EQ-5D, SF-6D, and 15D estimation equations from this
study produced an achievable range of utility scores, which was
in close proximity to that given by the standard scoring algo-
rithms, and, in the case of 15D, the predicted and standard
ranges were almost identical. It is also worth nothing that for the
three instruments, only one predicted utility score was “out of
range,” i.e., not achievable (speciﬁcally EQ-5D = 1.07) by the
standard scoring algorithms used in CUAs. These ﬁndings should
increase the conﬁdence placed on the validity of the prediction
equations. Utility indices calculated from the two OLS models
were compared with reported utilities derived directly from the
three instruments, and the level of correlation was assessed with
Pearson’s r, which was very high throughout. Also, mean scores
for predicted utilities were identical to the reported ones.
The three random subsamples that were used for “external”
validation conﬁrmed the previous results, i.e., the 15D model
was the one with the highest predictive ability, whereas the
EQ-5D model was the one with the lowest. To increase conﬁ-
dence in the validity of the prediction equations, the natural
subgroups used previously to test the validity of the QLQ-C30
scales were used again. Speciﬁcally, three sets of subgroups were
tested, i.e., patients <60 and 60 years, with and without coro-
nary disease, and mild versus potent chemotherapy (results not
shown). Predicted and reported utility values were very close in
magnitude and correlated strongly throughout (Pearson’s r was
similar to the values reported in Table 4). Although these results
may be regarded as encouraging, at least for SF-6D and 15D,
future studies involving larger and more diverse patient samples
are needed to better assess estimated prediction models. The
most obvious limitation in the present study was the size of the
sample, which may be regarded as relatively small despite repre-
senting major patient demographic and clinical variables on an
equal basis. Nevertheless, the results, which were tested using
standard methods typically employed in similar studies, were
quite encouraging, and when further validated, may contribute
to the aim of performing cost-utility analyses by means of the
EORTC’s QLQ-C30 alone.
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